Vera Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
55.9%projected annual EPS growth
Analyst Coverage
14analysts covering
FY Revenue (est.)
$25.5Mnext fiscal year
FY EPS (est.)
-$6.32next fiscal year
Monitoring Framework
Key Performance Indicators
Atacicept BLA Regulatory Approval Status (PDUFA Date)Target: FDA Approval on or before July 7, 2026
Cash, Cash Equivalents, and Marketable Securities596.8MTarget: Sufficient to fund operations through potential approval and U.S. commercial launch
PIONEER Phase 2 Basket Trial Initial ResultsTarget: Initial results expected in Q2 2026
ORIGIN 3 Phase 3 Trial eGFR Analysis TimelineTarget: Earlier eGFR analysis expected in Q3 2026
Watch Items
- Competitive pressure from Otsuka's Voyxact (sibeprenlimab)Trigger: Voyxact market penetration and clinical data comparison (e.g., 51.2% proteinuria reduction)Action: Evaluate commercial positioning, pricing strategy, and differentiation of atacicept's weekly autoinjector profile.
- Accelerated eGFR analysis data integrityTrigger: Q3 2026 eGFR analysis resultsAction: Assess if the earlier eGFR analysis supports a supplemental BLA submission in Q4 2026 for full FDA approval.
Research as of 19 Jun 2026